Metabolic syndrome in patients receiving antipsychotic therapy

被引：0
|
作者：
Le Guillouzic, D. [1 ]
机构：
[1] Hop Paul Guiraud, Villejuif, France
来源：
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION | 2011年 / 15卷 / 04期
关键词：
Metabolic syndrome; Visceral adiposity; Insulin resistance; Severe mental disorders; Antipsychotic; DRUG-NAIVE PATIENTS; ATYPICAL ANTIPSYCHOTICS; GLUCOSE-TOLERANCE; WEIGHT-GAIN; SCHIZOPHRENIA; PREVALENCE; RISPERIDONE; OLANZAPINE; DISEASE; RISK;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：101 / 106
页数：6
相关论文
共 50 条
  • [41] Does the metabolic syndrome affect the effectiveness of antipsychotic therapy for different durations of schizophrenia?
    Kornetova, E.
    Kornetov, A.
    Ivanova, S.
    EUROPEAN PSYCHIATRY, 2020, 63 : S246 - S246
  • [42] Antihypertensive therapy in patients with metabolic syndrome
    Segura, Julian
    Ruilope, Luis Miguel
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2006, 15 (05): : 493 - 497
  • [43] Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia
    Said, Mas Ayu
    Hatim, A.
    Habil, M. H.
    Zafidah, Wan
    Haslina, M. Y.
    Badiah, Y.
    Ramli, M. A.
    Ananjit, S.
    Sapini, Y.
    Shah, Mohd
    Mahmud, Badli
    Bulgiba, Awang
    Hairi, Noran N.
    PREVENTIVE MEDICINE, 2013, 57 : S50 - S53
  • [44] Improving Metabolic Syndrome Screening on Patients on Second Generation Antipsychotic Medication
    Kioko, Esther
    Williams, Kimberly
    Newhouse, Beth
    ARCHIVES OF PSYCHIATRIC NURSING, 2016, 30 (06) : 671 - 677
  • [45] Antipsychotic Treatment and Metabolic Syndrome: a Comparison Between Schizophrenic and Bipolar Patients
    Prisco, V.
    Boccardi, M.
    Fantini, C.
    Catapano, F.
    Fabrazzo, M.
    EUROPEAN PSYCHIATRY, 2015, 30
  • [46] Antipsychotic treatment and metabolic syndrome: a comparison between schizophrenic and bipolar patients
    Prisco, V.
    Fabrazzo, M.
    Catapano, F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S241 - S241
  • [47] Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy
    Kornetova, E. G.
    Dubrovskaya, V. V.
    Kornetov, A. N.
    Lobacheva, O. A.
    Ivanova, S. A.
    Semke, A., V
    BYULLETEN SIBIRSKOY MEDITSINY, 2018, 17 (04): : 54 - 64
  • [48] Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy
    Chow, Vincent
    Reddel, Caroline
    Pennings, Gabrielle
    Scott, Elizabeth
    Pasqualon, Tundra
    Ng, Austin C. C.
    Yeoh, Thomas
    Curnow, Jennifer
    Kritharides, Leonard
    SCHIZOPHRENIA RESEARCH, 2015, 162 (1-3) : 175 - 182
  • [49] Incidence of tardive dyskinesia in patients receiving first or second generation antipsychotic therapy
    Tapp, A.
    Wood, A.
    Kilzieh, N.
    Martin, L.
    Kennedy, A.
    Raskind, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S420 - S420
  • [50] Does the presence of metabolic syndrome affect platelet aggregation inhibition in patients receiving chronic aspirin therapy?
    Polena, S.
    Gupta, M. P.
    Shaikh, H.
    Rojkovskiy, I.
    Coplan, N.
    Soffer, D.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 374 - 374
12345